High frequency of potential interactions between direct‐acting antivirals and concomitant therapy in  HIV /hepatitis C virus‐coinfected patients in clinical practice | Zendy

Macías J | Zendy; Monge P | Zendy; Mancebo M | Zendy; Merchante N | Zendy; Neukam K | Zendy; Real LM | Zendy; Pineda JA | Zendy

Premium

High frequency of potential interactions between direct‐acting antivirals and concomitant therapy in HIV /hepatitis C virus‐coinfected patients in clinical practice

Author(s) -

Macías J,

Monge P,

Mancebo M,

Merchante N,

Neukam K,

Real LM,

Pineda JA

Publication year - 2017

Publication title -

hiv medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.53

H-Index - 79

eISSN - 1468-1293

pISSN - 1464-2662

DOI - 10.1111/hiv.12471

Subject(s) - ombitasvir , paritaprevir , dasabuvir , medicine , ledipasvir , daclatasvir , simeprevir , sofosbuvir , coinfection , concomitant , genotype , ritonavir , virology , hepatitis c , hepatitis c virus , viral load , human immunodeficiency virus (hiv) , virus , ribavirin , antiretroviral therapy , biochemistry , chemistry , gene

The aim of the study was to analyse the frequency and degree of potential drug-drug interactions (DDIs) between direct-acting antivirals (DAAs) and concomitant medication used by HIV/hepatitis C virus (HCV)-coinfected patients, including antiretroviral therapy (ART) and other drugs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research